Wealthy funder pays reparations for use of HeLa cells
By Alexandra Witze,
Nature
| 10. 29. 2020
Howard Hughes Medical Institute’s six-figure donation is a step towards addressing racial injustice in the sciences.
A major biomedical-research organization has for the first time aimed to make financial reparation for the continuing experimental use of cells from Henrietta Lacks, a Black woman who was the source of the historic ‘HeLa’ cell line, which has been a mainstay of biological research for decades. The Henrietta Lacks Foundation announced the six-figure gift from the Howard Hughes Medical Institute (HHMI) in Chevy Chase, Maryland, on 29 October.
In 1951, doctors took cancerous cells from Lacks without her consent, and later created the HeLa cell line, which today supports a multibillion-dollar biotechnology industry. Lacks died soon after, and for decades, her family saw no financial compensation and were not consulted on other medical decisions stemming from the use of the cells in research.
“We felt it was right to acknowledge Henrietta for the use of HeLa cells and to acknowledge that the cells were gained inappropriately,” says Erin O’Shea, president of the HHMI. “And to acknowledge that we have a long way to go before science and medicine are really equitable.” The HHMI did not disclose the exact amount...
Related Articles
By Sarah Zhang, The Atlantic | 03.18.2024
People are discovering the truth about their biological parents with DNA—and learning that incest is far more common than many think.
When Steve Edsel was a boy, his adoptive parents kept a scrapbook of newspaper clippings in their bedroom closet...
By Antonio Regalado, MIT Technology Review | 03.20.2024
There is a new most expensive drug ever—a gene therapy that costs as much as a Brooklyn brownstone or a Miami mansion, and more than the average person will earn in a lifetime.
Lenmeldy is a gene treatment for metachromatic...
By Gerry Smith, Bloomberg | 03.12.2024
When Celenise Mahmood first learned about two new gene therapies that could cure sickle cell disease, she felt a wave of relief.
Her 9-year-old son, Navid, has the inherited blood disorder. By age 5, he’d had over 30 life-saving blood...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...